ClinicalTrials.gov
public full text
Public Domain
tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr
The study is designed to assess the therapeutic efficacy of decitabine repurposing against advanced, refractory, ductal adenocarcinoma (PDAC) with molecular transcriptional signatures indicating dependency on the KRAS oncogene
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC#1139966
- Divergent surgical outcomes for CACNA1D- and KCNJ5-mutant aldosteronomas are traceable to their cell-of-origin and most differentially expressed gene, CCM2L#387628
- DHHC7 palmitoylates KRAS4A and promotes mutant KRAS-driven pancreatic cancers#151324
- DHHC7 palmitoylates KRAS4A and promotes mutant KRAS-driven pancreatic cancers#148841
- Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC#1074298
Record · ID 1104000
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive